Introduction: Pancreatic cancer (PC) is a progressive and very deadly disease with a very high and significant malignancy rate. With less than 5 years survival in patients with this type of cancer, this cancer is the second most common cancer among men in Iranian society after breast cancer in women. Of course, treatments such as surgery can provide 5-year survival for up to 25% of patients. Cancer cells in pancreatic cancer often spread to adjacent tissues such as the liver. Given the lack of appropriate screening methods for early detection of this type of cancer, early diagnosis of pancreatic cancer is often delayed. The findings suggest that several genes and signaling pathways are involved in the development and progression of pancreatic cancer.Mutations in tumor suppressor genes and oncogenes lead to intrauterine pancreatic neoplasia, the most common noninvasive complication of this cancer. These mutations directly affect the pharmacodynamic cycle. Based on these pharmacodynamic effects and the interplay between genetics and drug metabolism, targeted therapies based on personalized medicine can be considered based on the individual's genetic profile. To design a personalized medicine approach to pancreatic cancer, we need to know the spectrum of gene mutations, signaling pathways involved, and the interaction between genetic and pharmacogenetic characteristics. P53 and KRAS are among the most important factors involved in the progression of pancreatic cancer. Molecular modifications and molecular drug design based on drug design can inhibit the deleterious and progressive effects of P53 and KRAS. The use of specialized therapies such as T cell-based cell therapy that is dependent on human leukocyte antigen (HLA) can also be directly linked to the cancer cell. T cells can target tumor antigens and suppress them and inhibit their growth. Another method of personalized medicine based on cell therapy is the use of cord stem cells. Stem cells have the potential to differentiate into any type of cell or tissue. In stem cell-based cell therapy, cancer cells and tissues are removed, and new and modified cells replace the old tissue and cells.
Methods: Surveying different articles related to the subject in recent years with using several internet search engines like google chrome, PubMed, and Scopus.
Results: For the treatment of pancreatic cancer, specialized and personalized treatments based on personalized medicine are superior to older treatments such as chemotherapy. Due to the sensitivity of the tumor cell to chemotherapy, this treatment has undesirable results. In personalized medicine, molecules can be designed to inhibit the effects of suppressor genes such as KRAS and TP53, using the genetic properties of cancer cells. Cell therapy can also target tumor antigens as part of a personalized medicine based on T cells. Cell therapy using cord stem cells has the potential to replace new and modified tissues and cancerous cells.
Conclusion: In summary, recent studies can conclude that "personalized medicine" therapeutic approaches, such as the design of specific molecules that bind to tumor suppressor genes, T cells, and stem cells for cancer treatment, can be concluded. The pancreas is much more useful than chemotherapy. Also, due to its specificity and high stability, this treatment is unlikely to be relapsed and will not have the costs of drug and chemotherapy treatments.
Keywords: Pancreatic cancer, personalized medicine, cell therapy, drug design